Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control
Authors:
- 1 January 2017
- journal article
- case report
- Published by Springer Nature in Hormones
- Vol. 16 (1) , 84-91
Abstract
To present two female patients with acromegaly inadequately controlled with long-acting octreotide who were subsequently treated with the multireceptor-targeted somatostatin analogue pasireotide that over-suppressed IGF-1 levels. We report two patients who failed surgery and received long-acting octreotide 20-30 mg/month as part of two double-blind, Phase III clinical trials. After 6-12 months of octreotide treatment, both patients remained inadequately controlled and were switched to long-acting pasireotide 40 mg/month as part of a crossover extension phase. During the core phase of the studies the patients received octreotide 20-30 mg/month, but GH and IGF-1 levels remained above normal. They were switched to pasireotide 40 mg/month after 6 and 12 months, according to the study protocols. After crossover, GH and IGF-1 decreased and normalized, but continued treatment led to further reduction of IGF-1 to below the normal; these reduced levels mildly increased following pasireotide dose reduction to 20 mg/month. Tumour volume was reduced and the clinical signs and symptoms of acromegaly also improved. These patients achieved long-term biochemical control, tumour volume reduction and improvement of clinical signs/symptoms after switching from octreotide to pasireotide. IGF-1 over-suppression is observed in a few patients and requires dose adjustment of pasireotide.Keywords
This publication has 19 references indexed in Scilit:
- Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III studyBMC Endocrine Disorders, 2016
- Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegalyPituitary, 2015
- Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trialThe Lancet Diabetes & Endocrinology, 2014
- Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension studyPituitary, 2013
- Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective StudyThe Journal of Clinical Endocrinology & Metabolism, 2009
- Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extensionPituitary, 2009
- Control of IGF‐I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegalyClinical Endocrinology, 2008
- A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegalyClinical Endocrinology, 2007
- AcromegalyNew England Journal of Medicine, 2006
- High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, BelgiumThe Journal of Clinical Endocrinology & Metabolism, 2006